Compare Heron Therapeutics Inc (HRTX) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs NICE Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while NICE Ltd trades at $117.08 (market cap $6.81B). The key difference: NICE Ltd is far larger — about 100.1× Heron Therapeutics Inc's market cap, and NICE Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and NICE Ltd for 15 Days on average.
| HRTX | NICE | |
|---|---|---|
Market Cap | $68.01M | $6.81B |
Volume | 1,891,941 | 382,395 |
Sector | Health | Technology |
52-Week High | $1.49 | $137.68 |
52-Week Low | $0.27 | $83.15 |
Typical Hold Time | 35 Days | 15 Days |
Enterprise Value | $174.75M | $6.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
NICE trades at $117.76, up 1.15% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding expectations. Recent news highlights leadership in AI-driven contact center platforms and workplace innovation awards, supporting positive sentiment.
The outlook for NICE is positive, driven by AI revenue growth and solid fundamentals, but risks include margin compression from heavy AI investments and competitive pressures. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
